Research progress on the mechanism of microtubule inhibitors in vascular neoplastic diseases

doi:10.16352/j.issn.1001-6325.2023.02.327

Abstract

Abstract: Neovascular diseases involve multiple systems and organs and are a major category of diseases characterized by angiogenesis, including tumors, cardiovascular diseases and eye diseases. Microtubule inhibitors are a class of natural or synthetic drugs which inhibit neovascularization and block neovascularization through changing the state of microtubules. They may induce apoptosis and block cell cycle by affecting angiogenesis related genes and cytokines.

Key words: neovascular disease, microtubule inhibitors, tubes, mechanism

CLC Number:

FANG Siyin, LIU Chen, WU Jinhui. Research progress on the mechanism of microtubule inhibitors in vascular neoplastic diseases[J]. Basic & Clinical Medicine, 2023, 43(2): 327-331.

References 24

[1]	You B, Pan S, Gu M, et al. Extracellular vesicles rich in HAX1 promote angiogenesis by modulating ITGB6 translation[J].Extracell Vesicles, 2022,11:e12221.doi: 10.1002/jev2.12221.
[2]	Campanacci V, Urvoas A, Ammar Khodja L, et al. Structural convergence for tubulin binding of CPAP and vinca domain microtubule inhibitors[J]. Proc Natl Acad Sci USA,2022,119:e2120098119. doi:10.1073/pnas.2120098119.
[3]	Jiang J, Zhang H, Wang C, et al. 1-Phenyl-dihydrobenzoindazoles as novel colchicine site inhibitors: struc-tural basis and antitumor efficacy[J]. Eur J Med Chem,2019,177:448-456.
[4]	Chen H, Deng S, Wang Y, et al. Structure-activity relationship study of novel 6-Aryl-2-benzoyl-pyridines as tubulin polymerization inhibitors with potent antiprolifera-tive properties[J]. Med Chem,2020,63:827-846.
[5]	Yao Y, Huang T, Wang Y, et al. Angiogenesis and anti-leukaemia activity of novel indole derivatives as potent colchicine binding site inhibitors[J]. J Enzyme Inhib Med Chem,2022,37:652-665.
[6]	Agut R, Falomir E, Murga J, et al. Synthesis of combretastatin A-4 and 3'-aminocombretastatin A-4 derivatives with aminoacid containing pendants and study of their interaction with tubulin and as downregulators of the VEGF, hTERT and c-Myc gene expression[J]. Molecules,2020,25. doi: 10.3390/molecules25030660.
[7]	Gold M, Köhler L, Lanzloth C, et al. Synthesis and bioevaluation of new vascular-targeting and anti-angiogenic thieno[2,3-d]pyrimidin-4(3H)-ones[J].Eur J Med Chem,2020,189:112060.doi: 10.1016/j.ejmech.2020.112060.
[8]	Sung SJ, Kim HK, Hong YK, et al. Autophagy is a potential target for enhancing the anti-angiogenic effect of mebendazole in endothelial cells[J].Biomol Ther (Seoul),2019,27:117-125.
[9]	Wang M, Zhang C, Zheng Q, et al. RhoJ facilitates angiogenesis in glioblastoma via JNK/VEGFR2 mediated activation of PAK and ERK signaling pathways[J].Int J Biol Sci, 2022,18:942-955]
[10]	Sun M, Zhang Y, Qin J, et al. Synthesis and biological evaluation of new 2-methoxyestradiol derivatives: Potent inhibitors of angiogenesis and tubulin polymerization[J].Bioorg Chem,2021,113:104988. doi:10.1016/j.bioorg.2021.104988.
[11]	Sun M, Wang Y, Yuan M, et al. Angiogenesis, anti-tumor, and anti-metastatic activity of novel α-substituted hetero-aromatic chalcone hybrids as inhibitors of microtubule polymerization[J]. Front Chem, 2021,9:766201.doi: 10.3389/fchem.2021.766201.
[12]	Wang Y, Sun M, Wang Y, et al. Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency[J]. Eur J Med Chem,2021,225:113790. doi: 10.1016/j.ejmech.2021.113790.
[13]	Fan A, Wei J, Yang M, et al. Pharmacodynamic and pharmacokinetic characteristics of YMR-65, a tubulin inhibitor, in tumor-bearing mice[J]. Eur J Pharm Sci,2018,121:74-84.
[14]	Huang H, Yao Y, Hou G, et al. Design, synthesis and biological evaluation of tanshinone IIA-based analogues: potent inhibitors of microtubule formation and angiogenesis[J]. Eur J Med Chem,2021,224:113708. doi: 10.1016/j.ejmech.2021.113708.
[15]	Nie W, Wang B, Mi X, et al. Co-delivery of paclitaxel and shMCL-1 by folic acid-modified nonviral vector to overcome cancer chemotherapy resistance[J]. Small Methods,2021,5:e2001132. doi: 10.1002/smtd.202001132.
[16]	Elhemely MA, Belgath AA, El-Sayed S, et al. SAR of novel 3-arylisoquinolinones: meta-Substitution on the Aryl ring dramatically enhances antiproliferative activity through binding to microtubules[J].J Med Chem,2022,65:4783-4797.
[17]	Sun M, Qin J, Kang Y, et al. 2-Methoxydiol derivatives as new tubulin and HDAC dual-targeting inhibitors, displaying antitumor and antiangiogenic response[J].Bioorg Chem, 2022, 120: 105625. doi: 10.1016/j.bioorg.2022.105625.
[18]	Porcu E, Persano L, Ronca R, et al. The novel antitu-bulin agent TR-764 strongly reduces tumor vasculature and inhibits HIF-1alpha activation[J].Sci Rep, 2016: 6: 27886. doi: 10.1038/srep27886.
[19]	Xu L, Wang W, Meng T, et al. New microtubulin inhi-bitor MT189 suppresses angiogenesis via the JNK-VEGF/VEGFR2 signaling axis[J]. Cancer Lett,2018,416:57-65.
[20]	Cao Y, Wang J, Tian H, et al. Mitochondrial ROS accumulation inhibiting JAK2/STAT3 pathway is a critical modulator of CYT997-induced autophagy and apoptosis in gastric cancer[J]. Exp Clin Cancer Res,2020,39:119. doi: 10.1186/s13046-020-01621-y.
[21]	Macabrey D, Longchamp A, MacArthur MR, et al. Sodium thiosulfate acts as a hydrogen sulfide mimetic to prevent intimal hyperplasia via inhibition of tubulin polymerisation[J]. EBioMedicine, 2022,78:103954. doi: 10.1016/j.ebiom.2022.103954.
[22]	Izumi Y, Aoshima K, Hoshino Y, et al. Effects of combretastatin A-4 phosphate on canine normal and tumor tissue-derived endothelial cells[J]. Res Vet Sci, 2017,112:222-228.
[23]	Yang M, Su Y, Wang Z, et al. C118P, a novel microtubule inhibitor with anti-angiogenic and vascular disrupting activities, exerts anti-tumor effects against hepatocellular carcinoma[J]. Biochem Pharmacol,2021,190:114641. doi: 10.1016/j.bcp.2021.114641
[24]	Belzacq-Casagrande AS, Bachelot F, De Oliveira C, et al. Vascular disrupting activity and the mechanism of action of EHT 6706, a novel anticancer tubulin polymerization inhibitor[J]. Invest New Drugs,2013,31:304-319.